Nektar Therapeutics

NKTR Healthcare Biotechnology

Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.

35.78 1.94 −5.14%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
3/9
Altman Z
−17.07
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
425.95 326.82 1,437.69 1,421.55 1,138.01 795.58 545.97 330.70 261.29 266.27
Total non-current assets
142.92 182.05 712.49 555.81 400.76 321.61 164.63 67.33 42.56 14.14
Total Assets
568.87 508.87 2,150.17 1,977.36 1,538.77 1,117.19 710.60 398.03 303.85 280.41
Total current liabilities
72.22 56.16 82.00 353.89 115.78 85.20 68.20 51.27 61.40 53.54
Total non-current liabilities
408.52 364.88 350.60 218.07 345.69 352.48 275.76 215.78 181.71 137.04
Total liabilities
480.75 421.04 432.60 571.97 461.47 437.68 343.96 267.05 243.11 190.57
Common Equity (Total)
88.12 87.83 1,717.58 1,405.39 1,077.30 679.51 366.64 130.99 60.74 89.83
Shareholders Equity (Total)
88.13 87.83 1,717.58 1,405.39 1,077.30 679.51 366.64 130.99 60.74 89.83
Total Debt
246.46 245.21 246.95 252.89 320.00 291.00 258.00 — — —

Show all line items

In millions of $ except per-share values · columns are period end dates